CD8A and neoplasm: Neuromedin U (NMU) impairs the biological function of CD8+ T lymphocytes in the PDAC tumor microenvironment in an NMUR1-dependent manner, whereas blockade of lactate production by tumor cells restores NMU-mediated inhibition of the antitumor activity of CD8+ T lymphocytes, which provides a new idea for immunotherapy (94).